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Summary
Background: The venoms of predators have been an excellent
source of diverse highly specific peptides targeting ion
channels. Here we describe the first known peptide antagonist
of the nociceptor ion channel transient receptor potential
ankyrin 1 (TRPA1).
Results: We constructed a recombinant cDNA library encod-
ing w100 diverse GPI-anchored peptide toxins (t-toxins)
derived from spider venoms and screened this library by coex-
pression in Xenopus oocytes with TRPA1. This screen resulted
in identification of protoxin-I (ProTx-I), a 35-residue peptide
from the venom of the Peruvian green-velvet tarantula, Thrixo-
pelma pruriens, as the first known high-affinity peptide TRPA1
antagonist. ProTx-I was previously identified as an antagonist
of voltage-gated sodium (NaV) channels. We constructed a
t-toxin library of ProTx-I alanine-scanning mutants and
screened this library against NaV1.2 and TRPA1. This revealed
distinct partially overlapping surfaces of ProTx-I by which it
binds to these two ion channels. Importantly, this mutagenesis
yielded two novel ProTx-I variants that are only active against
either TRPA1or NaV1.2. By testing its activity against chimeric
channels, we identified the extracellular loops of the TRPA1
S1–S4 gating domain as the ProTx-I binding site.
Conclusions: These studies establish our approach, whichwe
term ‘‘toxineering,’’ as a generally applicable method for isola-
tion of novel ion channel modifiers and design of ion channel
modifiers with altered specificity. They also suggest that
ProTx-I will be a valuable pharmacological reagent for ad-
dressing biophysical mechanisms of TRPA1 gating and the9These authors contributed equally to this work
10Present address: Department of Physiology, University of Pennsylvania,
Philadelphia, PA 19104, USA
*Correspondence: michael.nitabach@yale.eduphysiology of TRPA1 function in nociceptors, as well as for
potential clinical application in the context of pain and
inflammation.
Introduction
Transient receptor potential (TRP) channels are diverse six-
transmembrane domain (6-TM) cation channels that are
related to, and share, the transmembrane topology and
functional domain structure of the tetrameric voltage-gated
ion channels. The first four transmembrane domains (S1–S4)
form the gating domain, while the S5 and S6 segments span
the re-entrant pore loop to form the selectivity filter and ion
conducting pore [1, 2]. TRP channels are involved in almost
all aspects of sensory transduction, including vision, olfaction,
mechanosensation, thermosensation, and physiological/path-
ological pain sensing [3]. Several dozen TRP channels have
been identified and are classified into six subfamilies,
including the TRP ankyrin family (TRPA), with varying degrees
of sequence similarity and permeability to cations [2]. TRPA1 is
the only member of the ankyrin subfamily so far identified in
mammals, and it contains at least 14 ankyrin repeats in the
N-terminal intracellular domain [4].
TRPA1 is activated by a variety of chemical compounds,
such as allyl isothiocyanate in mustard oil (MO), allicin in garlic
and onion [5, 6], and synthetic drugs such as clotrimazole [7],
chlorpromazine [8], and clioquinol [9]. TRPA1 can also be
activated by endogenous metabolic products and oxidative
stress-derived substances and sensitized through G protein-
coupled receptors (GPCRs) [10], cyclic adenosine monophos-
phate/protein kinase A (cAMP/PKA) [11], and protease
activated receptor 2 (PAR2) [12] signaling pathways. In mice,
TRPA1 is highly expressed in unmyelinated and thinly myelin-
ated sensory neurons of dorsal root ganglion (DRG), nodose
ganglion (NG), and trigeminal ganglion (TG) neurons [4, 13],
and expression in the urethra, urinary bladder, prostate gland,
and arteries has also been observed [14–18]. TRPA1 is co-
expressed with TRPV1 in many small-diameter nociceptor
sensory neurons that contain both substance P and calcitonin
gene-related peptide [4]. TRPA1 knockout mice exhibit pro-
nounced deficits in bradykinin-evoked nociceptor excitation
and pain hypersensitivity [10]. TRPA1 is upregulated in
inflammatory injury and neuropathic pain, and perturbation
of TRPA1 activity can protect against cold-induced hyperalge-
sia [19–24]. The central role for TRPA1 in pain sensation is
starkly highlighted by a gain-of-function TRPA1 mutation in
human patients suffering from familial episodic pain syn-
drome, in which patients suffer debilitating pain on fasting
and physical stress [25].
The importance of TRPA1 in pain signaling makes it a poten-
tial target for the treatment of pathological pain [26]. While
some small-molecule TRPA1 antagonists have been identified
[26, 27], no peptide antagonists of TRPA1 have been reported.
The venoms of predators, such as spiders, scorpions, cone
snails, sea anemones, and snakes, have been an excellent
source of peptide diversity for drug discovery and as pharma-
cological tools for elucidating the structure, function, and
physiological properties of ion channels [28, 29]. For example,
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474hanatoxin, a 35-residue peptide from Chilean rose tarantula
venom, has been invaluable for probing the structure and func-
tion of K+ channels [30, 31]. a-Bungarotoxin, a 74-residue pep-
tide from elapid snakes, has been an essential tool in the study
of nicotinic acetylcholine receptors [32]. A peptide toxin from
cone snail targeting CaV2.2 channels has already been devel-
oped into a Food and Drug Administration (FDA)-approved
treatment for intractable pain in human patients [33].
A key issue in ion channel toxin biology has been the mining
of this great pharmacological diversity—e.g., spiders alone are
estimated to collectively contain millions of distinct peptide
toxins in their venoms [28]—to identify toxins with high affinity
for particular ion channel targets. Here we report the develop-
ment and validation of a novel peptide toxin screening
platform utilizing the previously described ‘‘tethered-toxin’’
(t-toxin) recombinant expression method [34, 35] and its use
to identify the first known peptide antagonist of TRPA1. We
constructed a cDNA library containing w100 t-toxins derived
from published and unpublished spider toxin sequences
(Table S1 available online), each encoded in glycosyl phospha-
tidyl inositol (GPI)-anchored membrane-tethered form. By
screening this library through functional coexpression with
cloned ion channel subunits, we identified protoxin-I (ProTx-I),
a 35-residue peptide from the venom of the Peruvian green-
velvet tarantula, Thrixopelma pruriens, previously identified
as an antagonist of voltage-gated sodium (NaV) channels
[36, 37], as a high-affinity TRPA1 antagonist. We found that
ProTx-I inhibits both NaV and TRPA1 by binding to the S1–S4
gating domains of these distantly related 6-TM channels.
These studies establish screening of t-toxin libraries of native
and mutated toxins, which we term ‘‘toxineering,’’ as a gener-
ally applicable method for isolation of novel ion channel
modifiers and for design of ion channel modifiers with altered
target selectivity. They also suggest that ProTx-I will be a
valuable pharmacological reagent for addressing the biophys-
ical mechanisms of TRPA1 gating and the physiology and
pathophysiology of TRPA1 function in nociceptors, as well
as for potential clinical application in the context of pain and
inflammation.
Results
Screen of a Recombinant Membrane-Tethered Spider
Toxin Library for TRPA1 Antagonists
It has recently been demonstrated that peptide ion channel
toxins from venomous predators can be heterologously
expressed as fusion proteins covalently tethered to GPI
anchors inserted in the extracellular leaflet of the plasmamem-
brane [34, 35]. Various cysteine-rich toxins from snakes, cone
snails, and spiders have been expressed in t-toxin form, where
they exhibit identical pharmacological specificity to the native
toxins [34, 35]. We generated a t-toxin library of approximately
100 cysteine-rich toxin sequences, a combination of both
previously published and unpublished sequences from an
ongoing large-scale spider venom-gland transcriptomics
effort at the University of Queensland. Toxin sequences were
cloned into a t-toxin backbone plasmid comprising a trypsin
secretory signal sequence, glycine-asparagine repeat linker
with embedded c-Myc epitope tag, and GPI targeting
sequence from the mammalian Lynx1 peptide, a modulator
of the nicotinic acetylcholine receptor (nAChR) (Figure 1A)
[34, 35]. The plasmid contains an upstream bacteriophage
RNA polymerase promoter for cRNA synthesis. cRNAs of
each of the t-toxins were synthesized in vitro and randomlycombined into 14 pools of six or seven toxins each. Xenopus
oocytes were coinjected with each t-toxin pool and TRPA1
cRNA (Figure 1B). One pool of toxins significantly suppressed
the inward TRPA1 current induced by 100 mMmustard oil (MO)
(Figure S1A). Each t-toxin in the positive pool was then tested
individually by coinjection with TRPA1 cRNA (Figure S1B). This
enabled identification of ProTx-I, a spider toxin previously
shown to block several different voltage-gated ion channels
[36–38], as a TRPA1 antagonist (Figure 1C).
Soluble ProTx-I Is a High-Affinity TRPA1 Antagonist
In order to confirm that the observed activity of t-ProTx-I
against TRPA1 is not an artifactual consequence of its GPI
membrane-tethered configuration, we measured the activity
of chemically synthesized soluble ProTx-I against TRPA1.
We expressed TRPA1 in HEK293 cells and measured MO-
induced currentswith perforatedwhole-cell patch-clamp elec-
trophysiology. Inhibitory activity was defined as Itoxin / IRR,
where Itoxin is the current inhibited by bath-applied ProTx-I
and IRR is the current inhibited by ruthenium red (RR), a
nonspecific TRP channel pore blocker. As shown in Figures
2A and 2B, 1 mM soluble ProTx-I inhibits MO-induced currents
by 63%. Dose-response analysis of TRPA1 antagonism by sol-
uble ProTx-1 reveals maximum inhibition of 90.9% 6 2.3%,
and IC50 of 389 6 77 nM (Figure 2C). The binding of ProTx-I
to TRPA1 is reversible, as inhibition is completely relieved by
washout (Figure 2B). Antagonism of TRPA1 by soluble
ProTx-I was further confirmed by imaging of Ca2+ influx, as
shown in Figure S3A. We also tested the effect of soluble
ProTx-I on TRPV1, a thermosensitive and chemosensitive
TRP channel that plays an important role in pain signaling
[39]. ProTx-I (1 mM) has no significant effect on TRPV1 currents
(ANOVA, p = 0.39; Figure S3B). These results confirm that re-
combinant expression as a t-toxin faithfully recapitulates the
pharmacological activity of native ProTx-I. MO, like endoge-
nous tissue stress and injury signals such as 4-hydroxy-none-
nal (produced during oxidative stress), hydrogen peroxide,
hydroxyl radicals, and hypochlorite (produced by activated
neutrophils), activates TRPA1 via covalent modification of
the cysteine-rich intracellular C terminus [40–44]. We also
tested whether ProTx-I inhibits TRPA1 currents activated by
allosteric modulators that interact with transmembrane do-
mains, and not the intracellular C terminus, such as menthol
and carvacrol [41, 45, 46]. ProTx-I inhibits the Ca2+ influx
through TRPA1 activated with either menthol or carvacrol (Fig-
ures S3C and S3D). We also confirmed that ProTx-I inhibits
Ca2+ influx through native TRPA1 in cultured mouse dorsal
root ganglion nociceptors (Figure S3E). The relatively modest
magnitude of the effect on mouse nociceptor TRPA1 is ex-
plained by the weaker potency of ProTx-I against cloned
mouse TRPA1 versus human TRPA1, with 3 mMProTx-I having
a smaller effect on mouse TRPA1 than 1 mMProTx-I on human
TRPA1 (Figure S3F).
t-ProTx-I Inhibits Mammalian and Insect Voltage-Gated Na+
Channels
ProTx-I inhibits some subtypes of voltage-gated Na+, Ca2+,
and K+ channels [38, 47]. To test whether membrane-tethered
t-ProTx-I behaves similarly, we coexpressed t-ProTx-I with
NaV channels or with voltage-independent inward-rectifier
Kir4.1, which lacks a voltage-sensor domain (VSD) and only
possesses the S5–S6 pore-forming domain. When coex-
pressed with NaV1.2, t-ProTx-I inhibits w60% of the inward
Na+ current (Figures 3A and 3B). When coexpressed with the
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Figure 1. Recombinant Membrane-Tethered ICK Toxin Library Screen
(A) t-toxins are chimeric fusion proteins with an N-terminal secretory signal sequence, toxin sequence, hydrophilic linker incorporating a c-Myc epitope tag,
and a C-terminal GPI membrane-anchor targeting sequence. t-toxins are secreted, but remain covalently linked to the plasma membrane via GPI anchors,
where they can bind to target channels that are present on the same cell.
(B) Approximately 100 spider toxin sequences were cloned into a plasmid vector backbone containing the other elements of the t-toxin. cRNAs encoding
each t-toxin were transcribed in vitro, combined randomly in pools, and then coinjected into Xenopus laevis oocytes with cRNA encoding human TRPA1.
MO-induced currents were measured by two-electrode voltage clamp.
(C) Average TRPA1 currents induced by 100 mM MO when coexpressed with t-d-ACTX-Hv1a, negative-control toxin that inhibits NaV channel inactivation,
(‘‘control’’) or t-ProTx-I, normalized to the average for control. Error bars indicate the mean 6 SEM. n is indicated.
(D) Representative examples of recordings from oocytes coexpressing TRPA1with either t-ProTx-I or negative-control t-d-ACTX-Hv1a toxin as summarized
in (C).
See also Figure S1 and Table S1.
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475Drosophila para NaV channel, t-ProTx-I inhibits inward Na
+
current completely (Figures 3C and 3D). This suggests that
ProTx-I has higher affinity for insect than mammalian Na+
channels, presumably because this toxin has been tuned
during the course of spider-venom evolution to target the
voltage-gated channels of insect prey. Consistent with the
potency of t-ProTx-I at inhibiting para currents, bath-applied
soluble ProTx-I completely silences action potential firing in
a Drosophila whole-brain electrophysiological preparation
(Figure S2). In contrast, t-ProTx-I has no effect on kinetics or
amplitude of inward-rectifier K+ current (Figures 3E and 3F).
This leads to the hypothesis that ProTx-I binds to the S1–S4
gating domain that is common to ion channels with six TM
domains (TRP channels and voltage-gated channels), butlacking in the inward-rectifier K+ channels that only possess
the two pore-spanning TM domains.
Voltage- and Time-Dependent Unbinding of ProTx-I from
Voltage-Gated Na+ Channel
Binding of a-scorpion toxins and ProTx-II, another cysteine-
rich toxin from the Peruvian green-velvet tarantula, to the
VSD of NaV channels can be reversed by sustained membrane
depolarization [48–50]. This supports a model in which the
toxins dissociate more rapidly from the channel in the acti-
vated state than in the closed state, thereby stabilizing the
closed conformation [51]. To test whether ProTx-I inhibits
NaV channels by a similar mechanism, we imposed depolariz-
ing prepulses (+100mV) of varying duration, followed by 80ms
A B C
Figure 2. ProTx-1 Is a High-Affinity TRPA1 Antagonist
(A) Representative current-voltage curves for inhibition by 1 mMProTx-1 of MO-activated (50 mM) voltage-ramp currents in TRPA1-expressing HEK293 cells
measured with perforated-patch whole-cell voltage clamp.
(B) ProTx-1 (1 mM) suppressesw60% inward (Vh = 280 mV) and outward (Vh = 80 mV) MO-activated TRPA1 currents.
(C) Concentration-response curve for ProTx-1 inhibition of MO-activated inward TRPA1 current for cells held at 280 mV. Percent inhibition of the MO-
induced current is normalized to that of inhibition by 10 mM ruthenium red (RR), a nonspecific TRP channel blocker, on the same cell; IC50 = 389 6
77 nM. Each point represents the mean 6 SEM with n = 3–5 cells.
See also Figure S3.
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476at the hyperpolarized holding potential (2100 mV) to allow
recovery from fast inactivation, and then a test pulse
to +10 mV (Figure 4A). As shown in Figures 4B and 4C, depo-
larizing prepulses cause unbinding of t-ProTx-I from para
coexpressed in Xenopus oocytes, with the amplitude of the
unblocked current increasingwith the duration of the prepulse.
Bath-applied ProTx-I (200 nM) exhibits identical unbinding
kinetics, with complete reversal by a 1 s depolarizing prepulse
(Figures 4D and 4E). These results indicate that ProTx-I blocks
voltage-gated ion channel currents by dissociating more
slowly from, and thereby stabilizing, the closed conformation
of the activation voltage gate. Moreover, they establish that
GPI tethering has no effect on the mechanism of channel bind-
ing by ProTx-I.
Identification of Channel Binding Surfaces of ProTx-I by
Alanine-Scanning of t-ProTx-I
In order to identify the surface of ProTx-I that mediates its
binding to voltage-gated channels and TRPA1, we generated
a library of alanine-scanning mutants of t-ProTx-I, with each
non-Cys and non-Ala residue mutated individually to Ala.
This alanine-scanning approach has previously been used
with chemically synthesized and recombinantly expressed
peptide toxins to identify target binding surfaces [52–55]. We
screened this library against NaV1.2 and TRPA1 by coex-
pression in Xenopus oocytes and measurement with two-
electrode voltage clamp of voltage- or MO-induced currents.
Detailed results of these recordings with statistical compari-
sons are shown in Figure S4. Importantly, none of the alanine
mutants exhibit reduced t-ProTx-I surface expression, thus
ruling out expression or trafficking defects as causes of altered
activity (Figure S5). In order to visualize the target binding
surfaces, we mapped each residue whose mutation signifi-
cantly reduces t-ProTx-I inhibitory activity against TRPA1 or
NaV1.2 to the high-resolution structure of ProTx-I that we
determined using nuclear magnetic resonance spectroscopy
(Figure 5). Each of the side chains whose mutation to alanine
reduces inhibitory activity against either channel are located
on the toxin surface, except for Leu19, which is internal, sug-
gesting that the L19A mutation disrupts ProTx-I folding. TheTRPA1 binding surface (pharmacophore) comprises five side
chains, whereas ten residues make up the pharmacophore
for NaV1.2.
Three residues are in common between the two binding
surfaces: Ser22, Trp30, and Phe34. Importantly, mutation of
particular residues leads to t-ProTx-I variants that are specific
inhibitors of either TRPA1 or NaV1.2, but not the other, such as
t-ProTx-I (W5A) and t-ProTx-I (S22A) (Figure 5D). Of the six
charged residues of ProTx-I, three participate in channel bind-
ing—Arg3, Arg23, and Asp 31—but only with NaV1.2. The
involvement of both hydrophobic and charged side chains in
the interaction of ProTx-I with NaV1.2 and the larger binding
surface are consistent with the substantially higher affinity
of ProTx-I for voltage-gated channels (IC50 of 30–90 nM
[36]) compared with TRPA1 (389 nM; Figure 2). The sub-
stantial overlap of the ProTx-I surfaces that bind to TRPA1
and NaV1.2—three of the five TRPA1-binding side chains are
shared between the two pharmacophores—is compatible
with the hypothesis that ProTx-I binds to TRPA1 by a
similar S1–S4 gating mechanism as it does to voltage-gated
channels.
ProTx-I Binding to TRPA1 Involves the S1–S2 Extracellular
Loop
ProTx-I has been previously shown to bind to chimeric KV2.1
containing VSD II or VSD IV from rat NaV1.2 [47]. In combination
with the overlapping ProTx-I binding surfaces for NaV1.2 and
TRPA1 (Figure 5) and the mechanism of NaV1.2 inhibition
(Figure 4), this suggests that ProTx-I could inhibit TRPA1 by
binding to the extracellular face of its S1–S4 gating domain.
In order to test this hypothesis, we attempted to confer greater
sensitivity to ProTx-I on a less-sensitive 6-TM channel by
transplant of the TRPA1 S1–S2 extracellular loop. As shown
in Figure 6, both soluble and membrane-tethered ProTx-I
only slightly inhibit the inward currents of NaChBac bacterial
NaV channel expressed in oocytes [56]. In contrast, chimeric
NaChBac with the S1–S2 linker of TRPA1 is substantially in-
hibited by ProTx-I, either membrane tethered or soluble (Fig-
ure 6). Similar to NaChBac expressed in Xenopus oocytes,
bath-applied soluble ProTx-I suppresses the currents of the
A B
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Figure 3. t-ProTx-I Specifically Inhibits 6-TM Ion Channels
(A) When coexpressed with NaV1.2, t-ProTx-I inhibits peak depolarization-induced inward currents byw65% compared with t-PLTX-II, a negative-control
toxin specific for CaV channels. Error bars indicate the mean 6 SEM.
(B) Representative recording of inward currents induced by a series of increasing depolarizations from an oocyte coexpressing NaV1.2 either with t-PLTX-II
negative-control toxin or t-ProTx-I.
(C) t-ProTx-I completely inhibits depolarization-induced inward currents of the Drosophila para NaV channel. Error bars indicate the mean 6 SEM.
(D) Representative recording of inward currents from oocytes coexpressing para with t-PLTX-II or t-ProTx-I.
(E) Current-voltage relationship showing that t-ProTx-I has no effect on currents flowing through Kir4.1, an inward-rectifier K+ channel. Points indicate the
mean 6 SEM.
(F) Representative recording of currents induced by a series of increasing depolarizations of oocytes coexpressing Kir4.1 with either t-ProTx-I or t-d-ACTX-
Hv1a, a negative-control toxin that inhibits NaV inactivation.
See also Figure S2.
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477chimera expressed in HEK293 cells substantially more than
wild-type NaChBac (Figures 6E and 6F). Interestingly, the
S1–S2 loop chimera NaChBac channel expressed in oocytes
appears more sensitive to ProTx-I than when expressed in
HEK293 cells, as 200 nM ProTx-I suppresses oocyte currents
more than 3 mM ProTx-I suppresses HEK293 currents. This
greater antagonism of ProTx-I for the S1–S2 loop chimera
NaChBac supports the hypothesis that it inhibits TRPA1 by
the same mechanism as voltage-gated channels: slower
dissociation and stabilization of the closed conformation of
the S1–S4 gating domain.Discussion
We have developed and validated a generally applicable
platform for toxin discovery and functional analysis and have
identified ProTx-I as the first known peptide TRPA1 antagonist
by using this novel recombinant t-toxin library screening
approach. ProTx-I will be a valuable pharmacological reagent
for addressing the biophysical mechanisms of TRPA1 gating
and the physiology and pathophysiology of TRPA1 function
in nociceptors, as well as for potential clinical application in
the context of pain and inflammation. We also generated and
AB
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Figure 4. ProTx-I and t-ProTx-I Bind to and Stabilize Voltage-Gated Channel Activation Gate
(A) Voltage-clamp protocol starts with depolarizing prepulse step to +100 mV of varying duration ranging from 0 to 1,000 ms, 80 ms return to holding
potential of 2100 mV to allow recovery from inactivation, followed by a depolarizing test pulse to 210 mV to activate the channel.
(B) Inward currents recorded from a representative oocyte coexpressing para and t-ProTx-I increase in amplitude as the duration of the depolarizing
prepulse increases.
(C) Bar graph shows the dependence of peak current during the test pulse on the duration of the prepulse. Test pulse currents are normalized to that for the
1,000 ms prepulse. Error bars indicate the mean 6 SEM.
(D) Inward currents as in (B), but for an oocyte expressing only para and in the presence ofw200 nM bath-applied soluble ProTx-I.
(E) Bar graph as in (C) for oocytes expressing only para and in the presence ofw200 nM bath-applied soluble ProTx-I. Error bars indicate the mean6 SEM.
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ProTx-I and thereby identified the partially overlapping
surfaces of ProTx-I by which it binds to TRPA1 and NaV1.2
(Figure 5). Importantly, this mutagenesis has yielded novel
ProTx-I variants that are only active against either TRPA1
(W5A) or NaV1.2 (S22A) (Figure 5D). On the basis of these iden-
tified binding surfaces, further directed mutagenesis and
screening of tethered ProTx-I libraries should be a feasible
means to obtain variants with even higher affinity and speci-
ficity for TRPA1.
Comparison of the NaV1.2 binding surface of ProTx-I that we
identified here with the NaV1.5 binding surface of ProTx-II
previously identified by chemical synthesis of alanine mutants
[52] reveals that hydrophobic and electrostatic interactions
are important for both ProTx-I and ProTx-II binding to
voltage-gated Na+ channels. All tryptophans in both toxins
contribute to interactions with NaV channels (Figure S6). Forexample, Trp5, Trp27, and Trp30, whose mutation to alanine
completely abolishes ProTx-I inhibition of NaV1.2, are
conserved in ProTx-II, and theirmutation to alanine reduces af-
finity of ProTx-II for NaV1.5 [52]. Interestingly, with the excep-
tion of Trp27, all residues that are important for ProTx-I binding
toTRPA1 are not conserved in ProTx-II, whichmay explain why
ProTx-I, but not ProTx-II, binds to and inhibits TRPA1 (t-ProTx-
II was in the same screening pool as t-ProTx-I and when
subscreenedon itsownhadnoactivity againstTRPA1), despite
the fact that both toxins inhibit NaV channels [36, 37, 52].
We also compared our ProTx-I alanine-scanning results with
those obtained for the related toxin SGTx1 obtained by chem-
ical synthesis of alanine mutants. SGTx1, isolated from the
venomof the African featherleg baboon spiderStromatopelma
calceatum griseipes, inhibits the KV2.1 voltage-gated K
+ chan-
nel by binding to residues in the S3b and S4 helices of the VSD
[55]. ProTx-I and SGTx1 have roughly 50% sequence identity
Figure 5. NaV1.2 and TRPA1 Binding Surfaces of ProTx-I Mapped by t-ProTx-I Alanine Scanning
(A and B) A library of t-ProTx-I alanine-scanning mutants was screened by coexpression with TRPA1 or NaV1.2 in Xenopus oocytes, with MO- or voltage-
induced currents measured by two-electrode voltage clamp. Amino acids exhibiting significantly decreased inhibition of TRPA1 (A) or NaV1.2 (B) when
mutated to alanine are colored yellow on the ProTx-I structure. Structures are shown in two orientations, rotated by 180.
(C) Binding surfaces for both TRPA1 and NaV1.2 are mapped onto the ProTx-I structure. Orange indicates amino residues involved in binding toTRPA1, red
indicates amino acid residues involved in binding to NaV1.2, and green indicates amino acid residues involved in binding to both ion channels.
(D) Representative two-electrode voltage-clamp recordings of Xenopus oocytes coexpressing either NaV1.2 or TRPA1 with negative-control t-toxin (t-PLTX
for NaV1.2 and t-d-ACTX-Hv1a for TRPA1), wild-type t-ProTx-I, or the indicated alanine mutants of t-ProTx-I. t-ProTx-I (W5A) is strongly active against
TRPA1, but has very little activity against NaV1.2. Conversely, t-ProTx-I (S22A) is strongly active against NaV1.2, but has very little activity against TRPA1.
See also Figures S4–S6 and Table S5.
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Figure 6. ProTx-I Binding to TRPA1 Involves the S1–S2 Extracellular Loop
(A) When coexpressed in Xenopus oocytes with a chimera of NaChBac containing the extracellular S1–S2 loop of TRPA1, t-ProTx-I inhibits peak depolar-
ization-induced inward currents byw80% compared with t-L19A, a mutant ProTx-I that fails to inhibit either voltage-gated sodium channels or TRPA1. In
contrast, t-ProTx-I has no significant effect on inward currents of wild-type (WT) NaChBac expressed in oocytes. Error bars indicate the mean 6 SEM.
(B) Representative recording of inward currents from an oocyte coexpressing either WT or chimeric NaChBac with either t-ProTx-I or t-L19A.
(C) Bath-applied ProTx-I (w200 nM) suppressesw50%of peak depolarization-induced inward currents of the chimeric NaChBac channel, but onlyw20%of
the WT NaChBac. Error bars indicate the mean 6 SEM.
(D) Representative recordings of inward currents for an oocyte expressing either WT or chimeric NaChBac with or without the presence of bath-applied
soluble ProTx-I.
(E) ProTx-I (3 mM) inhibits peak depolarization-induced inward currents of chimeric NaChBac by w30%, but only w10% of WT NaChBac expressed in
HEK293 cells. Error bars indicate the mean 6 SEM.
(F) Representative recordings of the effects of 3 mM ProTx-I on NaChBac WT and chimeric NaChBac inward currents from HEK293 cells.
Current Biology Vol 24 No 5
480
Peptide Gating-Domain Antagonist of TRPA1
481(Figure S6). Leu19 in ProTx-I, which is buried inside the toxin as
shown in Figure 5 and is possibly involved in ProTx-I folding, is
conserved in SGTx1. In the solution structure of SGTx1, the
aliphatic side chain of Leu19 is also largely buried inside the
toxin, resulting inmisfolding of the L19Amutant [55]. As shown
in Figure 5, the NaV1.2 binding surface of ProTx-I involves a hy-
drophobic protrusion comprising the side chains of Trp5,
Trp30, and Val29, surrounded by nonhydrophobic residues
except Trp27 and Phe34, including Arg3, Ser22, Arg23,
Asp31, and Gly32. The topological disposition of these resi-
dues is quite similar to those in the KV2.1 binding surface
of SGTx1 [55]. These comparisons to related toxin-channel
binding interactions strongly suggest that screening of
alanine-scanning t-toxin libraries faithfully reveals the target
binding surfaces of native soluble toxins.
It has been reported that ProTx-I shifts NaV channel acti-
vation to more depolarized potentials, but has no effects on
inactivation [36, 37]. More recently, ProTx-I was shown to
bind to chimeric KV2.1 containing VSD II or VSD IV from rat
NaV1.2 [47]. Here, we found that ProTx-I impedes NaV channel
activation by binding to and stabilizing the voltage sensor in
its closed conformation (Figure 4). Taken together, these data
suggest that ProTx-I inhibits NaV1.2 by binding to one of the
VSDs, most likely the extracellular surfaces of VSDs in channel
domains II or IV. Furthermore, the partial overlap of the TRPA1
andNaV1.2bindingsurfacesofProTx-I and the lackof inhibition
of 2-TM inward-rectifer Kir4.1 suggest that ProTx-I binds to
TRPA1 by a similar S1–S4 gating mechanism as it does to
voltage-gated channels. Consistent with this hypothesis,
ProTx-I inhibits chimeric NaChBac bacterial channel with the
transplanted S1–S2 loop of TRPA1 more potently than wild-
type NaChBac (Figure 6). However, the extent of ProTx-I inhibi-
tion of the chimericNaChBac is less than of TRPA1 itself, which
suggests that ProTx-I binding to TRPA1 also involves other
parts of the S1–S4 extracellular surfaces (several other
NaChBac chimeras were also generated but failed to produce
stable currents). Regardless, these results indicate a common
conformational gating mechanism between TRP and voltage-
gated channels and establish ProTx-I as a valuable tool
for further detailed biophysical analysis of TRPA1 gating
mechanisms.
Compared to traditional biochemical fractionation ap-
proaches, there are several advantages of the toxineering
strategy. First, this method allows screening of large numbers
of toxins in equimolar fractions, unlike the highly skewed abun-
dances of toxins in native venoms [57]. Less-abundant toxins
maybepresent in too small a quantity in native venom todetect
their activity, or their activitymaybemaskedbymore abundant
ones. Second, toxineering avoids the need for obtaining native
venom or chemically synthesized and in vitro folded toxins.
Although various cysteine-rich peptide toxins have been suc-
cessfully generated in large quantities using either chemical
synthesis or recombinant expression in bacteria (e.g., [58,
59]), appropriate conditions for synthesis, expression, and
folding of each toxin have to be determined individually due
to distinct chemical and structural characteristics, which is
expensive and time consuming. Generation of complex t-toxin
libraries for screening requires nothingmore than diverse toxin
sequences—which are nowbeing generated in hugequantities
asa result of spider venom-gland transcriptomics efforts [60]—
and standard gene synthesis methods. This approach is thus
amenable to high-throughput scale up. Third, the toxineering
approach enables peptide toxin engineering and screening
without the need for chemical synthesis and in vitro folding oflarge numbers of variant peptides. Indeed, based as it is on
site-directedmutagenesis of cDNA, itwouldbestraightforward
to generate large-scale mutant t-toxin libraries and screen
them for variants with improved affinity and/or specificity
for desired targets. Toxineering thus provides a functional
screening alternative to the recently reported purely binding-
based phage display method [61].
Experimental Procedures
t-Toxin Design and Library Construction
All t-toxin sequences were generated by replacement of the sequence
encoding mammalian Lynx1, a toxin-like nicotinic acetylcholine receptor
modulator, by the cDNAs of toxins in frame between the secretion signal
and the lynx1 hydrophobic sequence for GPI attachment [34, 35]. A flexible
linker containing aglycine-asparagine repeatwas insertedbetween the toxin
and the hydrophobic sequence for GPI attachment, and a c-Myc epitope tag
was introduced in themiddle of the linker. t-toxin cDNAswere cloned into the
pCS2+ plasmid vector for in vitro transcription of t-toxin cRNA.
Loop NaChBac Chimera Design
A chimeric NaChBac channel was generated by substitution of the NaCh-
Bac S1–S2 extracellular loop (ETYPRIYADHKWL, residues 43–55, acces-
sion number NP_242367 in PubMed) with the S1–S2 extracellular loop of
TRPA1 (KPGMAFNSTGIINETSDHSEILDTTNSYLIKT, residues 741–772,
accession number O75762 in UniProt).
Two-Electrode Voltage Clamp
The gene constructs for cloning theDrosophila voltage-gated Na+ channel a
subunit (para) and its auxiliary b subunit (tipE), pGH19-13-5 para [62] and
pGH tipE, were fromM.Williamson (Rothamsted Research). Capped cRNAs
were prepared by restriction enzyme linearization, followed by in vitro tran-
scription reaction with SP6 or T7 RNA polymerase (mMessenger mMachine
kit, Ambion). Concentrations of cRNAs were measured by NanoDrop 2000
(Thermo Scientific), and all toxin cRNAs were diluted to 1 mg/ml. cRNAs of
toxins and ion channels of interest were mixed at 1:1 ratio (v/v) and injected
into the oocytes. For details of standard two-electrode voltage-clamp pro-
tocol, see the Supplemental Experimental Procedures.
HEK293 Cell Culture and Electrophysiology
Human embryonic kidney (HEK) 293 cells (ATCC, CRL-1573) were cultured
in Dulbecco’s modified Eagle’s medium (Lonza) supplemented with
10% fetal bovine serum (Lonza), 2 mM L-glutamine, 100 units/ml penicillin,
and 100 mg/ml streptomycin. Cells were transfected by lipofectamine
(Invitrogen). For details of the standard whole-cell voltage-clamp protocol,
see the Supplemental Experimental Procedures.
Statistical Analysis
All quantitative results are presented as mean 6 SEM. Statistical analyses
were performed using unpaired Student’s t test or ANOVA with paired com-
parisons with significance being concluded for p < 0.05.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, six figures, and two tables and can be found with this article online
at http://dx.doi.org/10.1016/j.cub.2014.01.013.
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